Hexameric VEGF Antagonists for Longer-Acting Ocular Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current VEGF-inhibitory therapeutics for angiogenic eye disorders require frequent intravitreal injections, causing discomfort and inconvenience to patients and healthcare providers, necessitating the development of VEGF antagonists with improved pharmacokinetic properties for less frequent dosing while maintaining efficacy.
Innovation Solution
Development of VEGF antagonists comprising a VEGF binding domain and a multimerization domain, including an IgG Fc domain and optionally an IgM tailpiece, forming hexameric structures that enhance pharmacokinetics and potency, such as hexameric VEGF antagonists with specific amino acid sequences and multimerization domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional VEGF-inhibitory therapeutics (monomeric or dimeric antibodies) are used, then therapeutic efficacy is achieved, but frequent intravitreal injections are required causing patient discomfort and provider burden
Solution Approach 1:
The patent merges multiple antibody molecules into a single hexameric complex through multimerization domains, creating a unified therapeutic unit that acts as six simultaneous monomeric units. This combining approach increases the duration of action and reduces injection frequency while maintaining efficacy.
Solution Approach 2:
The invention creates a composite protein structure combining six antibody molecules with specific multimerization domains (IgG Fc domains and IgM tailpieces) to form a hexameric complex. This composite structure provides enhanced pharmacokinetic properties including prolonged half-life and reduced clearance, directly addressing the need for less frequent dosing.
2Loss of time
If VEGF antagonists with improved pharmacokinetics are developed, then injection frequency is reduced, but structural complexity increases
Solution Approach 1:
The patent segments the antibody structure into distinct functional modules: VEGF binding domains (Ig-like domains 2 and 3) and multimerization domains (IgG Fc domains with IgM tailpieces). This segmentation allows independent optimization of binding functionality and multimerization capabilities, managing complexity through modular design.
Solution Approach 2:
The IgM tailpiece acts as an intermediary element that mediates the assembly of six antibody units into a hexameric structure through disulfide bond formation. This intermediary component simplifies the overall design by providing a standardized interface for multimerization without requiring complex cross-linking mechanisms.
3Reliability
If hexameric VEGF antagonists are used, then pharmacokinetic properties are improved and potency increased, but manufacturing complexity increases
Solution Approach 1:
The antibody molecules perform self-assembly through their inherent multimerization domains, forming hexameric complexes without requiring external cross-linking agents or complex purification steps. The IgM tailpieces automatically mediate assembly via disulfide bonds, simplifying manufacturing by eliminating the need for additional chemical or enzymatic cross-linking processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hexameric VEGF antagonists provide improved pharmacokinetics and potency, potentially reducing the frequency of injections and maintaining therapeutic efficacy for angiogenic eye disorders.
Implementation Method 1
The presence of IgM tailpieces allows the multimerization domains to assemble into polymeric structures via disulfide bonds involving a cysteine residue in the tailpiece
Data Source
AI summary
The present disclosure relates to VEGF antagonists. VEGF antagonists disclosed herein comprise a VEGF binding domain and a multimerization domain. Certain VEGF antagonists disclosed herein comprise five or more dimers, each dimer comprising two polypeptides, each polypeptide comprising a VEGF binding domain and a multimerization domain comprising an IgG Fc domain and, optionally, an IgM tailpiece. The disclosure further provides pharmaceutical compositions comprising the VEGF antagonists and methods of use of the VEGF antagonists in therapy, e.g., for treating angiogenic eye disorders. Also disclosed are nucleic acids encoding the VEGF antagonists, recombinant cells that express the VEGF antagonists, and methods of producing the VEGF antagonists.